[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-378268-105":59,"doc-detail-378268-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","concept-of-a-fully-implantable-system-to-monitor-tumor-recurrence","Concept of a fully-implantable system to monitor tumor recurrence","","Current glioblastoma management relies on surgical resection followed by radiotherapy, chemotherapy, and periodic postoperative examinations, yet recurrence remains common and often localized to the resection site. Standard MRI surveillance can miss or misinterpret histologic changes, complicating interpretation of adjuvant therapy and subsequent interventions. The proposal introduces an implantable system using optical sensing of fluorescently labeled cancer cells, integrated into the resection cavity, with experimental validation and extended wireless energy transfer electronics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/concept-of-a-fully-implantable-system-to-monitor-tumor-recurrence/378268/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/concept-of-a-fully-implantable-system-to-monitor-tumor-recurrence/378268.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is tumor recurrence monitoring difficult for glioblastoma patients?","Question",{"text":112,"@type":113},"Recurrence often occurs at the resection site, but conventional MRI surveillance can overlook or misinterpret histologic changes, such as effects that resemble pseudoprogression or pseudoresponse.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What core idea does the paper propose for recurrence monitoring?",{"text":117,"@type":113},"It proposes a fully implantable system that enables accurate continuous monitoring by using optical sensing of fluorescently labeled cancer cells implanted in the resection cavity during the final stage of resection.",{"name":119,"@type":110,"acceptedAnswer":120},"How was the implantable sensing approach validated?",{"text":121,"@type":113},"Feasibility was demonstrated using miniaturized system components, optical tissue phantoms, and porcine brain tissue in a series of experimental trials, followed by electronics extension for wireless energy transfer and power management.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},378268,1790678932,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nConcept of a fully‑implantable system to monitor tumor recurrence  \nAnna Schaufler1,2,3, Ahmed Y. Sanin1,4, I. Erol Sandalcioglu2, Karl Hartmann2, Roland S. Croner1,6, Aristotelis Perrakis1,6, Thomas Wartmann1, Axel Boese 3, Ulf D. Kahlert1,4 & Igor Fischer 5*  \nCurrent treatment for glioblastoma includes tumor resection followed by radiation, chemotherapy, and periodic post‑operative examinations. Despite combination therapies, patients face a poor prognosis and eventual recurrence, which often occurs at the resection site. With standard MRI imaging surveillance, histologic changes may be overlooked or misinterpreted, leading to erroneous conclusions about the course of adjuvant therapy and subsequent interventions. To address these challenges, we propose an implantable system for accurate continuous recurrence monitoring that employs optical sensing of fluorescently labeled cancer cells and is implanted in the resection cavity during the final stage of tumor resection. We demonstrate the feasibility of the sensing principle using miniaturized system components, optical tissue phantoms, and porcine brain tissue in a series of experimental trials. Subsequently, the system electronics are extended to include circuitry for wireless energy transfer and power management and verified through electromagnetic field, circuit simulations and test of an evaluation board. Finally, a holistic conceptual system design is presented and visualized. This novel approach to monitor glioblastoma patients is intended to early detect recurrent cancerous tissue and enable personalization and optimization of therapy thus potentially improving overall prognosis.  \nThe propensity of malignant tissue to accumulate substances with fluorescent properties has been known for many decades. Fluorescein has been reported as early as 19471,2, and the same tendency was observed on porphyrins in 19483,4. Many other markers have been discovered since and have entered diagnostic and clinical use5–8 etc. 5-aminolevulinic acid (5-ALA)-induced porphyrins have been in use as a marker in fluorescence-guided surgery of primary brain tumors since at least 19989.  \nMalignant gliomas are a major primary brain tumor type. Despite years of research, their etiology and origins are still unknown10. Glioblastoma multiforme (GBM) is their most malignant variant, accounting for almost 50% of malignant glioma, with an incidence of about 3.2 per year and 100,000 population in western countries11. Glioblastoma show a highly infiltrating growth pattern, rendering complete resection virtually impossible. Therefore, current treatment protocols combine resection with radiotherapy and chemotherapy. Still, the prognosis is poor: For the most common genetic form, IDH-wildtype, the median survival is only 10-15 months after surgery, and even for the less aggressive mutant form, which accounts for about 10% of the GBM cases, it is only 24–31 months12, 13. In spite of maximal primary resection and combination therapy, the 5-year survival rate for recurrent glioblastoma remains below 5%, with tumor recurrence being the leading cause of mortality occurring ata recurrence rate of approximately 90%. Here, approximately 70% of patients experience recurrence within the first year after diagnosis and in 90% of cases, disease progression manifests locally at the primary site within a boundary of less than 2 cm 14–16.  \n1Molecular and Experimental Surgery, Clinic for General-, Visceral-, Vascular-and Transplant Surgery, Faculty of Medicine, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany. 2Department of Neurosurgery, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany. 3INKA Health Tech Innovation Lab., Medical Faculty, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany. 4Research Campus STIMULATE, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany. 5Department of N","cbCaidz1MFj4afPC","https://ap.wps.com/l/cbCaidz1MFj4afPC","pdf",4688697,16,"English","# Concept and clinical need\n## Limits of current MRI surveillance\n# Proposed implantable optical system\n## Optical sensing during resection cavity implantation\n## Experimental feasibility trials\n# System electronics and validation\n## Wireless energy transfer and power management\n## Simulations and evaluation board testing\n# Related background and rationale\n## Fluorescence properties of malignant tissue\n## Fluorescence-guided surgery markers\n# Disease burden and recurrence patterns\n## Incidence, infiltrative growth, and survival\n## Timing and local manifestation of recurrence\n# Limitations of conventional imaging and alternatives\n## Pseudoprogression and pseudoresponse\n## Advanced MRI modalities and performance","[{\"question\":\"Why is tumor recurrence monitoring difficult for glioblastoma patients?\",\"answer\":\"Recurrence often occurs at the resection site, but conventional MRI surveillance can overlook or misinterpret histologic changes, such as effects that resemble pseudoprogression or pseudoresponse.\"},{\"question\":\"What core idea does the paper propose for recurrence monitoring?\",\"answer\":\"It proposes a fully implantable system that enables accurate continuous monitoring by using optical sensing of fluorescently labeled cancer cells implanted in the resection cavity during the final stage of resection.\"},{\"question\":\"How was the implantable sensing approach validated?\",\"answer\":\"Feasibility was demonstrated using miniaturized system components, optical tissue phantoms, and porcine brain tissue in a series of experimental trials, followed by electronics extension for wireless energy transfer and power management.\"}]","Concept of a fully-implantable system to monitor tumor recurrence | PDF",1790229248]